Minerva Surgical

UTRS · OTC

$0.0001+$0.00 (+0.00%)TodayMarket closed ·
No price history for this range.

About UTRS

Minerva Surgical, Inc. is a medical technology company. The company is headquartered in Santa Clara, California and currently employs 174 full-time employees. The company went IPO on 2021-10-22. The firm designs, manufactures, distributes, and commercializes a suite of products that offer effective alternatives to hysterectomy, with a focus on diagnosing and treating the underlying causes of Abnormal Uterine Bleeding (AUB). Its solutions are designed for use across a variety of care settings and focused on improving clinical outcomes and preserve uterine anatomy. The company delivers devices that treat the root causes of AUB in both the normal and irregular shaped uterus. The firm's products include Minerva ES Endometrial Ablation System (Minerva ES), Genesys HTA Endometrial Ablation System (Genesys HTA), Symphion Operative Hysteroscopy System (Symphion), Resectr Tissue Resection Device (Resectr), and HERizon Disposable Hysteroscope. Its Minerva EAS includes PlasmaSense Technology, which monitors uterine cavity. The company also provides HERizon Hysto-Kit, which supports in-office hysteroscopy.

Employees
174
Headquarters
Santa Clara, California
Listed
Oct 22, 2021
Sector
Health Care
Industry
Health Care Equipment & Supplies

Leadership

Minerva Surgical executives
NameTitleSince
Uri Geiger——
Todd Usen—2023
Joel Jung—2021
Dominique Filloux——
Evgueni Skalnyi——
Kaile Zagger——
Ali Behbahani——
Daniel Cohen——
Catherine Coste——
Niquette Hunt——
Derrick Sung——

Similar companies

Companies in the same industry as Minerva Surgical

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.